Who qualifies for Mounjaro on the NHS — and what the criteria actually mean

The biggest misconception: 'if my BMI qualifies, I qualify'

The most common misunderstanding our prescribers hear is that hitting a certain BMI number means automatic NHS access to Mounjaro. It does not. NICE's appraisal of tirzepatide (TA1026) recommended a phased approach specifically because demand for these medicines is so high, and because the NHS wanted to reach those with the most complex health needs first.

In the first phase, which opened in June 2025, the requirement is a BMI of 40 or above plus four or more of the following conditions: high blood pressure, dyslipidaemia (abnormal cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That is a combination most people simply do not have. Millions of adults in the UK who are overweight or obese, and who could clinically benefit from tirzepatide, fall outside this first cohort entirely, and that is not a reflection of whether treatment would help them.

If you are reading this while feeling frustrated by that gap, that is understandable. The science moved faster than the commissioning structure. The NICE appraisal is clear that tirzepatide works; the phasing is about NHS capacity, not clinical merit.

For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, NICE specifies thresholds 2.5 kg/m² lower, recognising that health risk at a given BMI differs across ethnic groups.

How the cohorts open up, and when

The NHS rollout follows a staged timetable set out by NHS England and based on NICE TA1026. Here is what the current plan looks like, drawn from NICE's published guidance and NHS England's commissioning information.

Cohort 1 (from June 2025): BMI 40 or above, four or more qualifying conditions. This cohort is already open. Cohort 2 (from around June 2026): BMI 35–39.9, again with four or more of the same five conditions, this phase was confirmed to have activated on 23 June 2026. Cohort 3 (from around March 2027): BMI 40 or above, but with only three qualifying conditions instead of four. Subsequent cohorts will continue to broaden access toward a BMI of 30 with at least one condition, though exact dates have not been confirmed.

From 1 April 2026, GP practices have been able to prescribe Mounjaro under the updated GP contract (QOF 2026/27). Participation is optional, not mandatory, so whether your own GP practice offers this will depend on local decisions. You can ask your GP surgery directly. Every NHS patient receiving these medicines must also take part in wraparound dietary and activity support, that is a condition of the programme, not an optional extra. Check which cohort you might fall into if you want to map your own situation against the timetable.

What happens if you do not yet meet the NHS threshold

A large proportion of people who are medically appropriate for tirzepatide do not currently meet the NHS criteria, or meet them on paper but face long waits while GP practices and specialist services scale up. That is the reality, stated plainly.

Private prescription is the legal alternative. A regulated online pharmacy with its own GPhC-registered prescribers can assess you against the medicine's licensed criteria, which are broader than the NHS criteria. The private licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. A prescriber still reviews your health history, weight, and any other relevant factors before any prescription is issued; the difference is that there is no waiting list and no requirement to hold a set number of comorbidities.

If you want to understand what the cost of Mounjaro through a private pharmacy typically looks like, that page sets out the market context honestly. And if you are already receiving treatment elsewhere and want to move to a new provider, switching is straightforward when you go through a regulated service.

NICE's appraisal of tirzepatide, which you can read in full at nice.org.uk/guidance/ta1026, gives the clinical background behind the NHS criteria. The NHS England page on weight management injections covers the wraparound care requirement and phased access in more detail.

Starting a private consultation if the NHS route is not open to you yet

If you fall into the gap (clinically suitable by the licensed criteria but not yet eligible on the NHS) a private consultation with a regulated prescriber is the appropriate next step. At nume, every consultation is read by a GPhC-registered Independent Prescriber. There is no algorithm making the decision. Your answers, your weight, and your medical history are reviewed by a real clinician on the same day you submit.

Verification is part of the process: photo ID and live weight confirmation before any prescription is written. If tirzepatide is clinically appropriate for you, treatment is dispatched the same day for next-working-day tracked delivery, in plain packaging. If it is not appropriate, you are told why, clearly, by someone qualified to explain it. You can find out more about who can access Mounjaro through a private route, or explore the full range of weight-loss treatments to see which might suit your situation best.